Profilo
Geoffrey A. Strange is currently the Chief Research & Strategy Officer at EchoIQ Ltd. and the Chief Medical Officer at LTR Pharma Ltd. Previously, he served as the Chief Executive Officer of The Pulmonary Hypertension Society of Australia & New Zealand from 2009 to 2021.
He also worked as the Global Medical Director at Anteris Technologies Ltd.
Posizioni attive di Geoffrey A. Strange
| Società | Posizione | Inizio |
|---|---|---|
| VERILUMA | Direttore Tecnico/Scientifico/R&S | - |
| LTR PHARMA LIMITED | Direttore Tecnico/Scientifico/R&S | - |
Precedenti posizioni note di Geoffrey A. Strange
| Società | Posizione | Fine |
|---|---|---|
The Pulmonary Hypertension Society of Australia & New Zealand
The Pulmonary Hypertension Society of Australia & New Zealand Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit patient association | Amministratore Delegato | 01/06/2021 |
Anteris Technologies Ltd.
Anteris Technologies Ltd. Medical SpecialtiesHealth Technology Engages in designing, developing and commercializing of medical devices to restore healthy heart function | Direttore Tecnico/Scientifico/R&S | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
Anteris Technologies Ltd.
Anteris Technologies Ltd. Medical SpecialtiesHealth Technology Engages in designing, developing and commercializing of medical devices to restore healthy heart function | Health Technology |
The Pulmonary Hypertension Society of Australia & New Zealand
The Pulmonary Hypertension Society of Australia & New Zealand Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit patient association | Commercial Services |
EchoIQ Ltd.
EchoIQ Ltd. Other Metals/MineralsNon-Energy Minerals Develops and commercializes software products | Non-Energy Minerals |
Ltr Pharma Ltd.
Ltr Pharma Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
















